>>42 . 27th symposium on Medicinal Chemistry in Eastern England: 21st April 2016 The Fielder Centre, Hatfield, Hertfordshire, UK 15.55 "Novel structure-based approaches to antagonism of Family B GPCRs" Andrea Bortolato, Heptares . BioTrinity 2016 - Europe's Leading Investment and Biopartnering Conference, 25-27, April, 2016 Participants: Heptares Therapeutics Ltd
6th Diabetes Partnering & Deal-Making Conference: April 25-27, 2016, Boston, MA 2016 Advisory Board Members: Dan Grau, Heptares Therapeutics April 26, 2016, Panel: "Equity Markets and Investment Trends in Diabetes and Obesity" 3:30 Moderator: Dan Grau President Heptares
European Pharma Summit 2016: Berlin, Germany. May 11-13, 2016 ・3rd GPCR Targeted Screening Conference: May 12-13, 2016 Scientific Advisory Board Members: Ali Jazayeri, Heptares Session: GPCR Structure and Dynamics May 13, 13:50, Robert Cooke Director, Biomolecular Structure, Heptaris
33rd Camerino-Cyprus Symposium: Camerino, May 15-19, 2016 Receptor Chemistry: Reality and Vision: Session Title: "Modeling GPCRs in the Structural Biology Era" "Revelations from GPCR Protein-Ligand Structures, with Key Roles for Water and the Prediction of Kinetics." : Jonathan Mason (Heptares, UK)
6th RSC / SCI symposium on GPCRs in Medicinal Chemistry, 13-15 June, 2016, Verona, Italy 13th June 09:30 ・Plenary: "The seventh millennium of GPCR drug discovery" Fiona Marshall, Heptares (UK) 14th June 11:30 ・Jonathan Mason, Heptares (UK): ”Roles of waters to predict binding affinity, selectivity and kinetics: a key component of high end GPCR SBDD” The key role of G-protein coupled receptors (GPCRs) in human disease underpins their importance to modern medicine. Takeda and Heptares are also confirmed sponsors.
Next Generation Protein Therapeutics, June 13-15, 2016, San Francisco, CA June 14, 2016 9:15; "Recombinant GPCRs as Targets for Biopharmaceutical Development" NEW DATA Stabilized receptors provide a breakthrough solution that addresses the essential challenge of reliably generating functional antibodies targeting GPCRs. This technology enables production of purified, correctly folded receptor protein that can be removed from the cell membrane and utilized as antigen. Catherine Hutchings, Ph.D., Consultant, Antibody Alliance Management & Strategic Partnering, Heptares, UK
School of Chemistry University of Leeds: Organic seminars 22/06/2016: Miles Congrev (Heptares)